These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38683569)

  • 1. Waitlisting and liver transplantation for MetALD in the United States: An analysis of the UNOS national registry.
    Ochoa-Allemant P; Serper M; Wang RX; Tang H; Ghandour B; Khan S; Mahmud N
    Hepatology; 2024 Apr; ():. PubMed ID: 38683569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
    Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
    Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.
    Ochoa-Allemant P; Marrero JA; Serper M
    Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38051551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study.
    Moon JH; Jeong S; Jang H; Koo BK; Kim W
    EClinicalMedicine; 2023 Nov; 65():102292. PubMed ID: 37954905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up.
    Kwak M; Kim HS; Jiang ZG; Yeo YH; Trivedi HD; Noureddin M; Yang JD
    Hepatology; 2024 May; ():. PubMed ID: 38739848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steatotic liver disease-associated all-cause/cause-specific mortality in the United States.
    Kim D; Wijarnpreecha K; Cholankeril G; Ahmed A
    Aliment Pharmacol Ther; 2024 Jul; 60(1):33-42. PubMed ID: 38649335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
    Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
    Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
    Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of MASLD and MetALD on clinical outcomes: A meta-analysis of preliminary evidence.
    Ciardullo S; Mantovani A; Morieri ML; Muraca E; Invernizzi P; Perseghin G
    Liver Int; 2024 Aug; 44(8):1762-1767. PubMed ID: 38597738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
    Lee BP; Dodge JL; Terrault NA
    Hepatology; 2024 Mar; 79(3):666-673. PubMed ID: 37732946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality.
    Tamaki N; Kimura T; Wakabayashi SI; Umemura T; Kurosaki M; Loomba R; Izumi N
    Aliment Pharmacol Ther; 2024 Jul; 60(1):61-69. PubMed ID: 38664876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex disparities in waitlisting and liver transplant for acute liver failure.
    Nephew LD; Zia Z; Ghabril M; Orman E; Lammert C; Kubal C; Chalasani N
    JHEP Rep; 2021 Feb; 3(1):100200. PubMed ID: 33511336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Steatotic Liver Disease Based on a New Nomenclature in the Japanese Population: A Health Checkup-Based Cross-Sectional Study.
    Miwa T; Tajirika S; Imamura N; Adachi M; Horita R; Hanai T; Fukao T; Shimizu M; Yamamoto M
    J Clin Med; 2024 Feb; 13(4):. PubMed ID: 38398471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.
    Fukuda T; Okamoto T; Fukaishi T; Kawakami A; Tanaka M; Yamada T; Monzen K
    Front Endocrinol (Lausanne); 2024; 15():1392280. PubMed ID: 38779448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
    Lee CM; Yoon EL; Kim M; Kang BK; Cho S; Nah EH; Jun DW
    Hepatology; 2024 Jun; 79(6):1393-1400. PubMed ID: 38100294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Risks of Cirrhosis and Hepatocellular Carcinoma Across Steatotic Liver Disease Subtypes.
    Chen YT; Chen TI; Yang TH; Yin SC; Lu SN; Liu XR; Gao YZ; Lin CJ; Huang CW; Huang JF; Yeh ML; Huang CF; Dai CY; Chuang WL; Yang HI; Yu ML; Lee MH
    Am J Gastroenterol; 2024 Apr; ():. PubMed ID: 38534155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the landscape of steatotic liver disease in the general US population.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International Travel for Liver Transplantation: A Comprehensive Assessment of the Impact on the United States Transplant System.
    Braun HJ; Amara D; Shui AM; Stock PG; Hirose R; Delmonico FL; Ascher NL
    Transplantation; 2022 Feb; 106(2):e141-e152. PubMed ID: 34608102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study.
    Han E; Lee BW; Kang ES; Cha BS; Ahn SH; Lee YH; Kim SU
    Metabolism; 2024 Mar; 152():155789. PubMed ID: 38224909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
    Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU
    Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.